PriceTargets.com logo

Freeline Therapeutics - FRLN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 2,234.81%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.43 As of 03/23/2023 01:00 AM ET
▲ +0.01 (2.39%)

This chart shows the closing price for FRLN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Freeline Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FRLN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FRLN

Analyst Price Target is $10.00
▲ +2,234.81% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Freeline Therapeutics in the last 3 months. The average price target is $10.00, with a high forecast of $15.00 and a low forecast of $5.00. The average price target represents a 2,234.81% upside from the last price of $0.43.

This chart shows the closing price for FRLN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Freeline Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/29/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/28/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/22/2022HC WainwrightLower TargetBuy$20.00 ➝ $15.00Low
8/11/2022BTIG ResearchLower TargetBuy$10.00 ➝ $5.00Low
2/11/2022Stifel NicolausReiterated RatingBuyLow
2/1/2022Morgan StanleyDowngradeOverweight ➝ Equal WeightHigh
1/7/2022Redburn PartnersUpgradeNeutral ➝ BuyLow
12/14/2021WedbushLower TargetOutperform$12.00 ➝ $10.00High
12/12/2021BTIG ResearchReiterated RatingBuy$10.00Medium
11/29/2021BTIG ResearchInitiated CoverageBuy$10.00High
8/18/2021HC WainwrightLower TargetBuy$30.00 ➝ $20.00Low
8/17/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$27.00 ➝ $8.00Medium
8/16/2021MizuhoDowngradeBuy ➝ NeutralLow
5/19/2021HC WainwrightInitiated CoverageBuy$30.00High
5/6/2021GuggenheimInitiated CoverageBuy$17.00High
4/6/2021Morgan StanleyLower TargetOverweight$28.00 ➝ $22.00High
3/29/2021MizuhoInitiated CoverageBuy$27.00N/A
3/22/2021MizuhoInitiated CoverageBuy$27.00High
3/1/2021Stifel NicolausInitiated CoverageBuy$21.00Medium
11/25/2020Redburn PartnersInitiated CoverageNeutralLow
9/1/2020Evercore ISIInitiated CoverageOutperformHigh
9/1/2020WedbushInitiated CoverageOutperform$28.00 ➝ $28.00High
9/1/2020JPMorgan Chase & Co.Initiated CoverageOverweight$27.00High
9/1/2020Morgan StanleyInitiated CoverageOverweight$28.00N/A
(Data available from 3/23/2018 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/25/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/24/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/24/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/23/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/23/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/22/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/21/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/23/2023

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Freeline Therapeutics logo
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
Read More

Today's Range

Now: $0.43
Low: $0.40
High: $0.52

50 Day Range

MA: $0.53
Low: $0.42
High: $0.63

52 Week Range

Now: $0.43
Low: $0.39
High: $1.29

Volume

109,098 shs

Average Volume

102,034 shs

Market Capitalization

$27.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.51

Frequently Asked Questions

What sell-side analysts currently cover shares of Freeline Therapeutics?

The following Wall Street research analysts have issued reports on Freeline Therapeutics in the last twelve months: BTIG Research, and HC Wainwright.
View the latest analyst ratings for FRLN.

What is the current price target for Freeline Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Freeline Therapeutics in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 2,234.8%. HC Wainwright has the highest price target set, predicting FRLN will reach $15.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $5.00 for Freeline Therapeutics in the next year.
View the latest price targets for FRLN.

What is the current consensus analyst rating for Freeline Therapeutics?

Freeline Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FRLN will outperform the market and that investors should add to their positions of Freeline Therapeutics.
View the latest ratings for FRLN.

What other companies compete with Freeline Therapeutics?

Other companies that are similar to Freeline Therapeutics include Solid Biosciences, SAB Biotherapeutics, IN8bio, ERYTECH Pharma and Entera Bio. Learn More about companies similar to Freeline Therapeutics.

How do I contact Freeline Therapeutics' investor relations team?

Freeline Therapeutics' physical mailing address is STEVENAGE BIOSCIENCE CATALYST GUNNELS WOOD ROAD STEVENAGE, HERTFORDSHIRE X0, SG12FX. The company's listed phone number is 44-0-14-3890-6870 and its investor relations email address is [email protected] The official website for Freeline Therapeutics is www.freeline.life. Learn More about contacing Freeline Therapeutics investor relations.